down arrow

Seres Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81750R1023
USD
17.90
1.2 (7.19%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

16.8017.90

52 Week

6.5329.98
Valuation
Technical
Day's Volume

CASH

116.03 k

Shareholding (Mar 2025)

FII

4.20%

Held by 61 FIIs

DII

50.76%

Held by 32 DIIs

Promoter

13.57%

How big is Seres Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Seres Therapeutics, Inc. has a market capitalization of 63.92 million, with net sales of 0.00 million and a net profit of -66.86 million over the last four quarters. The company reported shareholder's funds of 13.78 million and total assets of 139.81 million as of Dec 24.

Market Cap: As of Jun 18, Seres Therapeutics, Inc. has a market capitalization of 63.92 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Seres Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -66.86 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 13.78 million and total assets of 139.81 million.

Read More

What does Seres Therapeutics, Inc. do?

22-Jun-2025

Seres Therapeutics, Inc. is a microbiome therapeutics company focused on developing Ecobiotic therapies to restore health by repairing dysbiotic microbiomes. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $63.92 million.

Overview: <BR>Seres Therapeutics, Inc. is a microbiome therapeutics platform company engaged in developing Ecobiotic microbiome therapeutics to restore health by repairing dysbiotic microbiomes, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: 33 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 63.92 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -132.49% <BR>Price to Book: 1.27<BR><BR>Contact Details: <BR>Address: 200 Sidney St, CAMBRIDGE MA: 02139-4218 <BR>Tel: ['1 617 9459626', '1 617 2033467'] <BR>Fax: 1 302 6555049 <BR>Website: http://serestherapeutics.com/

Read More

Who are in the management team of Seres Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Seres Therapeutics, Inc. includes Independent Chairman Mr. Stephen Berenson, President and CEO Mr. Eric Shaff, and several Independent Directors: Dr. Dennis Ausiello, Mr. Gregory Behar, Mr. Paul Biondi, Dr. Willard Dere, and Mr. Kurt Graves.

As of March 2022, the management team of Seres Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Stephen Berenson, who serves as the Independent Chairman of the Board.<BR>- Mr. Eric Shaff, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Dennis Ausiello, who is an Independent Director.<BR>- Mr. Gregory Behar, who is also an Independent Director.<BR>- Mr. Paul Biondi, serving as an Independent Director.<BR>- Dr. Willard Dere, who is another Independent Director.<BR>- Mr. Kurt Graves, who is an Independent Director as well.<BR><BR>This team comprises a mix of executive leadership and independent directors.

Read More

Is Seres Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Seres Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a negative ROCE and ROE, and has underperformed the S&P 500, making it a less appealing investment compared to its peers.

As of 8 July 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its current financial metrics, particularly with a Price to Book Value of 1.42 and an EV to Capital Employed ratio of 22.07, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the negative ROCE of -11917.50% and ROE of -132.49% highlight the company's struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, Seres Therapeutics has a less favorable valuation profile, with Terns Pharmaceuticals, Inc. showing a more negative P/E of -6.9440 and Humacyte, Inc. at -1.8479, indicating that these companies are also facing challenges but are priced lower relative to their earnings potential. Over the past year, Seres Therapeutics has underperformed the S&P 500, returning -14.14% compared to the index's 17.14%, reinforcing the notion that the stock is not a compelling investment at its current valuation.

Read More

Is Seres Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Seres Therapeutics, Inc. shows a bullish technical trend, supported by positive MACD and moving averages, despite underperforming the S&P 500 over the past month and year.

As of 19 August 2025, the technical trend for Seres Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish on the weekly and mildly bullish on the monthly. The KST shows a bullish trend weekly and mildly bullish monthly, while the OBV is mildly bearish weekly but mildly bullish monthly. <BR><BR>In terms of returns, the stock has outperformed the S&P 500 over the past week with a return of 2.62% compared to the S&P 500's 1.05%, but it has underperformed over the past month, year-to-date, and year. Overall, the current technical stance is bullish, driven primarily by the positive signals from MACD and moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 200 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-163.41%

stock-summary
Price to Book

6.07

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.24%
0%
-3.24%
6 Months
155.71%
0%
155.71%
1 Year
2.08%
0%
2.08%
2 Years
-16.36%
0%
-16.36%
3 Years
151.05%
0%
151.05%
4 Years
-91.62%
0%
-91.62%
5 Years
-96.46%
0%
-96.46%

Seres Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Seres Therapeutics, Inc. technically bullish or bearish?

As of 19 August 2025, the technical trend for Seres Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. Bollinger Bands are bullish on the weekly and mildly bullish on the monthly. The KST shows a bullish trend weekly and mildly bullish monthly, while the OBV is mildly bearish weekly but mildly bullish monthly. In terms of returns, the stock has outperformed the S&P 500 over the past week with a return of 2.62% compared to the S&P 500's 1.05%, but it has underperformed over the past month, year-to-date, and year. Overall, the current technical stance is bullish, driven primarily by the positive signals from MACD and moving averages....

Read More

Is Seres Therapeutics, Inc. overvalued or undervalued?

As of 8 July 2024, the valuation grade for Seres Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued given its current financial metrics, particularly with a Price to Book Value of 1.42 and an EV to Capital Employed ratio of 22.07, which suggests that the market is pricing the company at a premium despite its poor performance. Additionally, the negative ROCE of -11917.50% and ROE of -132.49% highlight the company's struggles in generating returns for shareholders. In comparison to its peers, Seres Therapeutics has a less favorable valuation profile, with Terns Pharmaceuticals, Inc. showing a more negative P/E of -6.9440 and Humacyte, Inc. at -1.8479, indicating that these companies are also facing challenges but are priced lower relative to their earnings potential. Over the past year, Seres Therapeutics has...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-10.87%
EBIT to Interest (avg)
-23.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
1.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
59.76%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.42
EV to EBIT
-0.19
EV to EBITDA
-0.20
EV to Capital Employed
22.07
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11917.50%
ROE (Latest)
-132.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 34 Schemes (31.47%)

Foreign Institutions

Held by 61 Foreign Institutions (4.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 39.51% vs -170.60% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.80",
          "val2": "-32.50",
          "chgp": "26.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "3.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.90",
          "val2": "-32.90",
          "chgp": "39.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 1,678.87% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.64% vs 54.56% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "126.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.40",
          "val2": "-92.20",
          "chgp": "-12.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "13.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-125.80",
          "val2": "-113.70",
          "chgp": "-10.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-849.20%",
          "chgp": "84.92%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-23.80
-32.50
26.77%
Interest
0.00
3.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.90
-32.90
39.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 39.51% vs -170.60% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
126.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-103.40
-92.20
-12.15%
Interest
0.00
13.20
-100.00%
Exceptional Items
-3.30
0.00
Consolidate Net Profit
-125.80
-113.70
-10.64%
Operating Profit Margin (Excl OI)
0.00%
-849.20%
84.92%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 1,678.87% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -10.64% vs 54.56% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Seres Therapeutics, Inc. stock-summary
stock-summary
Seres Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
Company Coordinates stock-summary
Company Details
200 Sidney St , CAMBRIDGE MA : 02139-4218
stock-summary
Tel: 1 617 94596261 617 2033467
stock-summary
http://serestherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."